Gilead pays $7.8bn to take full control of promising multiple myeloma therapy

Gilead agreed to acquire clinical-stage Arcellx for $7.8 billion ($115 per share cash, a 68% premium to the 30-day VWAP as of Feb 20) plus a $5-per-share contingent value right payable if anito-cel achieves ≥$6bn cumulative global net sales through 2029. Gilead, which already owns ~11.5% of Arcellx, expects the deal to close in Q2 2026; anito-cel (a BCMA-directed CAR T for relapsed/refractory multiple myeloma) has an FDA PDUFA date of 23 Dec 2026 and the company says the acquisition would be EPS-accretive from 2028 assuming approval, while also adding Arcellx's D-domain CAR platform for future programs.

Analysis

Market structure: Gilead (GILD) converts a strategic minority stake into full control of anito-cel for $7.8bn ($115/sh + $5 CVR if ≥$6bn sales through 2029), immediately consolidating its BCMA CAR‑T exposure and advantaging its commercial scale and payer access. Direct winners are GILD (long‑term optionality, EPS accretive from 2028 if approved) and ACLX shareholders (68% premium today); near‑term losers are smaller CAR‑T pure‑plays that lack balance‑sheet scale and could lose pricing leverage in later lines.

Risk assessment: Key tail risks are a CRL or delayed PDUFA (23 Dec 2026) that would wipe substantial value from the $7.8bn purchase, manufacturing shortfalls for autologous CAR‑T, and integration/late‑stage trial disappointments; probability-weighted downside could exceed 30% in a negative catalyst. Immediate (days) risk is deal financing noise and stock wobble; short term (weeks–months) is regulatory readouts and capacity build; long term (years) is payer adoption, label expansion, and platform monetization.

Trade implications: Tactical plays include a 2–3% long position in GILD (12–24 month hold) to capture rerating if approval occurs, plus a capped-risk LEAP call spread (~0.5–1% allocation) expiring Jan 2028 to lever the PDUFA outcome. Merger‑arb: if ACLX trades < $113 pre‑close, buy to capture spread to $115 (target IRR ≥15% annualized if close by Q2); consider pairing long GILD vs short a CAR‑T pure‑play (e.g., BMY neutral/short small allocation) to express re‑rating.

Contrarian angles: Consensus underprices execution complexity — manufacturing scale and payer pushes could delay revenue, making the $6bn CVR threshold hard to reach; GILD may have overpaid if label is constrained to late lines. Market reaction (-1.5% GILD) understates integration and capex needs; a negative PDUFA or manufacturing hiccup could compress GILD ~15–30%, creating a tactical buying opportunity.

Key Decisions for Investors

• Establish a 2–3% long position in GILD with a 12–24 month horizon to capture EPS accretion from 2028 and potential rerating if anito‑cel is approved; trim if Gilead issues >$3bn debt or EPS guidance is lowered.
• Allocate 0.5–1% to a defined‑risk LEAP call spread on GILD expiring Jan 2028 (buy near‑ATM call, sell higher strike to fund) to lever the Dec 23, 2026 PDUFA outcome while capping downside.
• If ACLX trades below $113 pre‑close (before expected Q2 close), purchase ACLX shares as merger arbitrage to capture the $115 cash consideration (and potential $5 CVR value); target spread >2% after costs and exit at deal close or sooner if counterparty/financing headlines emerge.
• Implement a relative‑value pair: go long GILD and short a smaller CAR‑T peer (small position vs BMY or a focused CAR‑T ETF equivalent) for 6–12 months to express scale/market‑share capture while hedging sector risk; rebalance after PDUFA or 1Q post‑close integration updates.